|Articles|July 1, 2004

Genaera begins more squalamine trials

Genaera Corp. will begin three phase II trials on squalamine, its systemically administered anti-angiogenic drug.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME